E-Separation Solutions
Wednesday morning?s session, ?Achievements and Challenges in Mass Spectrometry,? was arranged by Imma Ferrer and Michael Thurman of the University of Colorado. Starting out the session will be Thurman with his opening remarks on the state of mass spectrometry.
Wednesday, March 3, 2010
Room 206A
Wednesday morning’s session, “Achievements and Challenges in Mass Spectrometry,” was arranged by Imma Ferrer and Michael Thurman of the University of Colorado. Starting out the session will be Thurman with his opening remarks on the state of mass spectrometry.
The first presentation will be given by Jennifer S. Brodbelt from the University of Texas. Brodbelt’s talk, “Photodissociation for Bioanalysis Mass Spectrometry,” will set an interesting tone for the rest of the session.
Following Brodbelt will be Jim Hager, of MDS Analytical Technologies, with “Recent Advances in Hybrid Linear Ion Trap Mass Spectrometry.” This 30-minute presentation will offer participants insight into the advances made in this area of mass spec.
Next up is session organizers Imma Ferrer and Michael Thurman with a presentation entitled, “Food Additives as Tracers of Wastewater Using Advanced Mass Spectrometry Techniques: The “Low Fat” Diet Impact.” Ferrer will lead the discussion and offer valuable information to the audience.
The next presentation will be given by Paul Zavitsanos and Bill Russ from Agilent Technologies. Their presentation, “The History and Development of the Triple Quadrupole Mass Spectrometer: State-of-the-Art and Future Developments,” will be an interesting take on the instrument side of mass spectrometry advances and challenges.
Finally, Nils Rehmann from the Research and Productivity Council will present, “Discovery of New Analogs of the Marine Biotoxin Azaspiracid in Blue Mussels (Mytilus edulis) by Ultra-performance Liquid Chromatography/tandem Mass Spectrometry.” This discussion will be approach the LC-MS aspect and offer new and exciting information to the audience.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.